[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tang Zhouping\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100620717","subthalamic-nucleus-stn-targeted-transcranial-temporal-interference-stimulation-tis-treats-parkinsons-disease-100620717",false,"NCT07361250","Subthalamic Nucleus (STN) Targeted Transcranial Temporal Interference Stimulation (TIS) Treats Parkinson's Disease","Evaluation of the Efficacy and Safety of Transcranial Temporal Interference Stimulation (TIS) Targeting the Subthalamic Nucleus (STN) in Parkinson's Disease: A Single-Center, Prospective, Double-Blind, Randomized Controlled Clinical Trial","TIS-STN-PD1","Inclusion Criteria:\n\n1. Age 18 years or older, no gender restriction;\n2. Diagnosis of primary Parkinson's disease according to MDS criteria: specifically, the patient must (a) exhibit parkinsonism (bradykinesia + resting tremor\u002Frigidity); (b) not meet any of the MDS absolute exclusion criteria; and (c) meet at least two MDS supportive criteria.\n3. Disease duration ≥1 year, stable condition;\n4. Hoehn-Yahr stage between 1.5 and 3, with a stable dose of levodopa or other dopaminergic medications for at least 4 weeks, responsive to levodopa-like medications, and no changes to the treatment regimen during the trial;\n5. Good compliance, with the patient and family willing to participate in the clinical trial, voluntarily sign the informed consent form, attend regular treatments and follow-ups, and accurately complete evaluation tasks.\n\nExclusion Criteria:\n\n1. Severe cognitive impairment, resulting in poor compliance due to dementia, and\u002For inability to sign the informed consent form;\n2. History of severe psychiatric disorders, patients with a Hamilton Depression Scale (HAMD) score \\>24;\n3. History of taking antipsychotic drugs, antidepressants, or other medications that may affect dopamine levels;\n4. History of seizures within the last year or a family history of epilepsy;\n5. Unable to complete MRI scanning (e.g., due to claustrophobia, or having metal implants in the body);\n6. Patients with severe heart, liver, or kidney diseases, severe hypertension, and severe orthostatic hypotension that affect their health condition;\n7. Patients with severe diabetes or severe cardio-cerebrovascular diseases that affect their health condition;\n8. Diagnosed with malignant tumors;\n9. Contraindications for non-invasive electrical stimulation, such as intracranial active implants (regardless of whether they are turned on) or passive implants that may affect electrical stimulation treatment, those who have undergone stereotactic deep brain stimulation or neurotomy, or have had any surgical procedures within the last six months that the investigator believes may affect this trial;\n10. History of traumatic brain injury;\n11. Pregnant women or women planning to become pregnant;\n12. Subjects currently participating in other clinical trials or have participated in other clinical research within the last three months without reaching primary endpoints;\n13. Patients deemed unsuitable to participate in this clinical study by the investigators.","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a single-center, prospective, double-blind, randomized controlled trial to evaluate the efficacy and safety of transcranial temporal interference stimulation targeting the subthalamic nucleus in patients with Parkinson's disease. It plans to enroll 20 eligible participants who will be randomly assigned in a 1:1 ratio to either the active TIS stimulation group or the sham stimulation group.",[27],"Parkinson Disease",[27,29,30],"Temporal Interference Stimulation","Subthalamic Nucleus (STN)","NOT_YET_RECRUITING","2026-01-14",{"date":34,"type":35},"2026-01-22","ACTUAL",{"date":37,"type":21},"2026-01-20",{"date":39,"type":21},"2027-06-20",{"name":41,"class":42},"Tang Zhouping","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100582367","phase-1-stem-cell-therapy-for-intracerebral-hemorrhage-100582367","NCT06862388","Stem Cell Therapy for Intracerebral Hemorrhage","Clinical Research on Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Subacute Intracerebral Hemorrhage","Inclusion Criteria:\n\n1. Age 18-65 years old, gender is not limited.\n2. Clinically confirmed intracerebral hemorrhage during the subacute period (3 days-10 days after onset).\n3. CT confirmed as cerebral parenchymal hemorrhage, ABC\u002F2 method to calculate the episodic hemorrhage volume of 15-30 mL (ABC\u002F2 method hematoma volume calculation formula V (cm3) =A×B×C×1\u002F2, A is the longest diameter of the largest level of the hematoma in the horizontal position of the CT scan (cm), B is the widest diameter of the hematoma in this plane perpendicular to the A (cm), C is the thickness of the hematoma appearing in the CT film (cm)).\n4. Blood biochemical indexes meet the following conditions: 1) good coagulation function, international normalized ratio (INR) \\\u003C2; 2) alachlor aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 times the upper limit of the normal value, and total bilirubin \\\u003C2 times the upper limit of the normal value; 3) creatinine clearance \\>50 mL\u002Fmin; 4) hemoglobin \\>90 g\u002FL; 5) absolute neutrophil value (ANC) ≥ 1.5×10\\^9\u002FL, absolute lymphocyte count ≥0.4×10\\^9\u002FL, platelet count ≥80×10\\^9\u002FL, and albumin \\>25g\u002FL; 6) procalcitonin (PCT) ≤2ng\u002FmL.\n5. National Institutes of Health Stroke Scale score (NIHSS) ≥5 and ≤20.\n6. Pre-onset modified Ranking Scale score (mRS) ≤1.\n7. Glasgow Coma Score (GCS) ≥9 points and ≥3 points on a single item.\n8. Good compliance, signed informed consent by the person and\u002For legal guardian and able to receive follow-up visits at the specified time.\n\nExclusion Criteria:\n\n1. Brain midline deviation \\>10 mm or brain hernia formation.\n2. Patients who have undergone or intend to undergo surgical treatment to remove hematoma.\n3. Secondary intracerebral hemorrhage caused by traumatic brain injury, arteriovenous malformation, intracranial aneurysm, coagulation disorders, hemorrhagic transformation after cerebral infarction, or tumors.\n4. Suffering from malignant tumors, autoimmune diseases (including but not limited to systemic lupus erythematosus, systemic vasculitis, etc.), hemorrhagic predisposition diseases (including all kinds of hereditary hemorrhagic disorders and acquired hemorrhagic diseases), malignant cardiac arrhythmia, cardiac insufficiency (BNP ≥1000pg\u002FmL or left ventricular ejection fraction ≤40%), acute myocardial infarction, acute or severe infectious diseases (such as intracranial infection, severe pneumonia, sepsis, etc.) and other serious diseases that may aggravate the condition and affect the assessment of efficacy.\n5. Allergy or intolerance to stem cell preparations or related medicines that need to be used in the infusion process, such as saline preparations and hormone preparations.\n6. Pregnant or lactating women.\n7. History of stroke disease with sequelae in the last 1 year, NIHSS score ≥ 6.\n8. Subarachnoid hemorrhage, primary ventricular hemorrhage, pharmacological hemorrhagic stroke.\n9. Unstable vital signs, including combined respiratory abnormalities (respiratory rate \\\u003C12 breaths\u002Fmin or \\>24 breaths\u002Fmin, oxygen saturation ≤90%), hyperthermia (axillary temperature \\>39 ℃), blood pressure ≥180\u002F100 mmHg after antihypertensive treatment, blood glucose \\>20 mmol\u002FL.\n10. Those who are participating in other clinical trials.\n11. Previous history of epilepsy or current use of antiepileptic drugs.\n12. Unable to accept all laboratory tests and imaging tests designed by the program due to metal implants or pacemakers in the body.\n13. Inability to complete the follow-up program as required.\n14. Patients or their legal guardians are unwilling to sign the written informed consent.","65 Years",{"count":52,"type":21},39,[54,55],"PHASE1","PHASE2","Intracerebral hemorrhage (ICH) is a common condition with high morbidity, mortality, and disability. The current treatments for ICH primarily include surgical and pharmacological interventions. For large hematomas, surgical options such as craniotomy, debridement, decompression, and minimally invasive hematoma aspiration may be performed. Pharmacological treatments are mainly symptomatic. Despite timely and standardized surgical or pharmacological interventions, many patients with ICH still experience significant sequelae, which severely affect their quality of life and place a substantial burden on both families and society. Currently, there are limited drugs available specifically for the treatment of ICH.\n\nIn recent years, stem cell therapy has gained attention as a promising treatment for neurological diseases. Human umbilical cord mesenchymal stem cells (UC-MSCs) are multifunctional stem cells with properties such as self-renewal, multidirectional differentiation potential, tissue repair, immunomodulation, and anti-inflammatory effects. Studies have shown that intravenous transplantation of UC-MSCs is safe, and their application in the treatment of ICH can reduce hematoma volume, attenuate cerebral edema and inflammation, and promote the recovery of neurological function. These findings offer a novel therapeutic strategy for ICH.\n\nThe purpose of this clinical trial is to evaluate the safety and efficacy of UC-MSCs transplantation in patients with subacute intracerebral hemorrhage, and providing a potential new therapeutic approach for this challenging condition.",[58,59],"Intracerebral Hemorrhage","Mesenchymal Stem Cell",[61,62,63,64,65],"Intracerebral hemorrhage","Human umbilical cord mesenchymal stem cells","Stem cell therapy","Inflammation","Neural repair","2025-03-02",{"date":68,"type":35},"2025-03-06",{"date":70,"type":21},"2025-03-01",{"date":72,"type":21},"2027-07-31",{"name":41,"class":42},""]